相似文献
1
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Lancet Infect Dis. 2020 Sep;20(9):1013-1014. doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.
2
Baricitinib for COVID-19: a suitable treatment?
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
3
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.
4
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
Expert Opin Drug Saf. 2020 Oct;19(10):1367-1369. doi: 10.1080/14740338.2020.1812191. Epub 2020 Aug 25.
5
Predictors of arrhythmia other than QT interval prolongation and the use of β-blocker therapy in the coronavirus disease 2019 pandemic. Authors' reply.
Kardiol Pol. 2020 Aug 25;78(7-8):796-797. doi: 10.33963/KP.15564.
6
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
7
Can artificial intelligence identify effective COVID-19 therapies?
EMBO Mol Med. 2020 Aug 7;12(8):e12817. doi: 10.15252/emmm.202012817. Epub 2020 Jul 7.
8
[Baricitinib in the treatment of SARS-CoV-2 infection].
Rev Esp Quimioter. 2020 Aug;33(4):294-295. doi: 10.37201/req/047.2020. Epub 2020 Jun 25.
9
Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Authors' reply.
Pol Arch Intern Med. 2020 Oct 29;130(10):922-923. doi: 10.20452/pamw.15662.
10
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
引用本文的文献
1
Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.
Drug Des Devel Ther. 2024 Sep 20;18:4215-4240. doi: 10.2147/DDDT.S475005. eCollection 2024.
2
Polypharmacology guided drug repositioning approach for SARS-CoV2.
PLoS One. 2023 Aug 9;18(8):e0289890. doi: 10.1371/journal.pone.0289890. eCollection 2023.
3
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
4
Drug development process and COVID-19 pandemic: Flourishing era of outsourcing.
Indian J Pharmacol. 2022 Sep-Oct;54(5):364-372. doi: 10.4103/ijp.ijp_318_22.
5
Abnormal Airway Mucus Secretion Induced by Virus Infection.
Front Immunol. 2021 Sep 28;12:701443. doi: 10.3389/fimmu.2021.701443. eCollection 2021.
6
Inflammatory Mechanism and Clinical Implication of Asthma in COVID-19.
Clin Med Insights Circ Respir Pulm Med. 2021 Sep 24;15:11795484211042711. doi: 10.1177/11795484211042711. eCollection 2021.
7
Recent advances and developments in COVID-19 in the context of allergic diseases.
Clin Transl Allergy. 2021 Sep;11(7):e12065. doi: 10.1002/clt2.12065.
8
Repurposing Vandetanib plus Everolimus for the Treatment of -Mutant Diffuse Intrinsic Pontine Glioma.
Cancer Discov. 2022 Feb;12(2):416-431. doi: 10.1158/2159-8290.CD-20-1201. Epub 2021 Sep 22.
9
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges.
Front Microbiol. 2021 Aug 25;12:637554. doi: 10.3389/fmicb.2021.637554. eCollection 2021.
10
How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.
Front Immunol. 2021 Jun 11;12:646894. doi: 10.3389/fimmu.2021.646894. eCollection 2021.
本文引用的文献
1
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
2
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
3
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
4
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.
J Clin Invest. 2019 Jul 29;129(9):3625-3639. doi: 10.1172/JCI126363.
5
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome.
J Virol. 2007 Aug;81(16):8692-706. doi: 10.1128/JVI.00527-07. Epub 2007 May 30.
Zotero 插件